Ridaforolimus: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Protected "Ridaforolimus": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(One intermediate revision by one other user not shown)
Line 4: Line 4:
| verifiedrevid = 464382356
| verifiedrevid = 464382356
| IUPAC_name = (1''R'',2''R'',4''S'')-4-[(2''R'')-2-[(1''R'',9''S'',12''S'',15''R'',16''E'',18''R'',19''R'',21''R'',23''S'',24''E'',26''E'',28''Z'',30''S'',32''S'',35''R'')-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0<sup>4,9</sup>]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphinate
| IUPAC_name = (1''R'',2''R'',4''S'')-4-[(2''R'')-2-[(1''R'',9''S'',12''S'',15''R'',16''E'',18''R'',19''R'',21''R'',23''S'',24''E'',26''E'',28''Z'',30''S'',32''S'',35''R'')-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0<sup>4,9</sup>]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphinate
| image = Deforolimus.svg
| image = Deforolimus.png


<!--Clinical data-->
<!--Clinical data-->

Latest revision as of 17:04, 20 August 2015

Ridaforolimus
Clinical data
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC53H84NO14P
Molar mass990.22 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Ridaforolimus

Articles

Most recent articles on Ridaforolimus

Most cited articles on Ridaforolimus

Review articles on Ridaforolimus

Articles on Ridaforolimus in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Ridaforolimus

Images of Ridaforolimus

Photos of Ridaforolimus

Podcasts & MP3s on Ridaforolimus

Videos on Ridaforolimus

Evidence Based Medicine

Cochrane Collaboration on Ridaforolimus

Bandolier on Ridaforolimus

TRIP on Ridaforolimus

Clinical Trials

Ongoing Trials on Ridaforolimus at Clinical Trials.gov

Trial results on Ridaforolimus

Clinical Trials on Ridaforolimus at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ridaforolimus

NICE Guidance on Ridaforolimus

NHS PRODIGY Guidance

FDA on Ridaforolimus

CDC on Ridaforolimus

Books

Books on Ridaforolimus

News

Ridaforolimus in the news

Be alerted to news on Ridaforolimus

News trends on Ridaforolimus

Commentary

Blogs on Ridaforolimus

Definitions

Definitions of Ridaforolimus

Patient Resources / Community

Patient resources on Ridaforolimus

Discussion groups on Ridaforolimus

Patient Handouts on Ridaforolimus

Directions to Hospitals Treating Ridaforolimus

Risk calculators and risk factors for Ridaforolimus

Healthcare Provider Resources

Symptoms of Ridaforolimus

Causes & Risk Factors for Ridaforolimus

Diagnostic studies for Ridaforolimus

Treatment of Ridaforolimus

Continuing Medical Education (CME)

CME Programs on Ridaforolimus

International

Ridaforolimus en Espanol

Ridaforolimus en Francais

Business

Ridaforolimus in the Marketplace

Patents on Ridaforolimus

Experimental / Informatics

List of terms related to Ridaforolimus

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ridaforolimus (also known as AP23573 and MK-8669; formerly known as Deforolimus[1]) is an investigational targeted and small-molecule inhibitor of the protein mTOR, a protein that acts as a central regulator of protein synthesis, cell proliferation, cell cycle progression and cell survival, integrating signals from proteins, such as PI3K, AKT and PTEN known to be important to malignancy. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis.

It has had promising results in a clinical trial for advanced soft tissue and bone sarcoma.

Commercial arrangements

Ridaforolimus is being co-developed by Merck and ARIAD Pharmaceuticals. On May 5, 2010, Ariad Pharmaceuticals and Merck & Company announced a clinical development and marketing agreement. With this agreement, Ariad received $125 million in upfront payments from Merck and $53 million in milestone payments. Future payments are triggered upon acceptance of the NDA by the FDA with another payment when the drug receives marketing approval. There are similar milestones for acceptance and approval in both Europe and Japan. Other milestone payments are tied to revenue goals for the drug.[2] ARIAD has opted to co-promote ridaforolimus in the U.S. Merck plans to submit a New Drug Application (NDA) for ridaforolimus to the U.S. Food and Drug Administration (FDA) and a marketing application in the European Union in 2011.[3] After formal rejection by the FDA in June 2012 ARIAD/MSD decided to withdraw their EMA application for Ridaforolimus in November 2012. [4]

Clinical trials

Phase III SUCCEED

On June 6, 2011, Ariad and Merck announced detailed results from the largest randomized study ever in the soft tissue and bone sarcoma population, the Phase III SUCCEED clinical trial. SUCCEED evaluated oral ridaforolimus, in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy. In this patient population, ridaforolimus improved progression-free survival (PFS) compared to placebo, the primary endpoint of the study. The complete study results were presented by Sant P. Chawla, M.D., director, Sarcoma Oncology Center, Santa Monica, CA, during the 2011 American Society of Clinical Oncology (ASCO) annual meeting.
The SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus) trial was a randomized (1:1), placebo-controlled, double-blind study of oral ridaforolimus administered at 40 mg/day (five of seven days per week) in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy. Oral ridaforolimus was granted a Special Protocol Assessment (SPA) by the FDA for the SUCCEED trial.
Based on 552 progression-free survival (PFS) events in 711 patients, (ridaforolimus (N=347), placebo (N=364) determined by an independent radiological review committee, the study achieved its primary endpoint of improvement in PFS, with a statistically significant (p=0.0001) 28 percent reduction in the risk of progression or death observed in those treated with ridaforolimus compared to placebo (hazard ratio=0.72). Median PFS was 17.7 weeks for those treated with ridaforolimus compared to 14.6 weeks in the placebo group. Furthermore, based on the full analysis of PFS determined by investigator assessment, there was a statistically significant (p<0.0001) 31 percent reduction by ridaforolimus in the risk of progression or death compared to placebo (hazard ratio=0.69). In the investigator assessment analysis, median PFS was 22.4 weeks for those treated with ridaforolimus compared to 14.7 weeks in the placebo group [5]


References

  1. "ARIAD Reports First Quarter 2009 Development Progress and Financial Results- Ridaforolimus New USAN Name to Replace Deforolimus". ARIAD Pharmaceuticals. 2009. Retrieved 2009-05-07.
  2. "ARIAD - News release". Phx.corporate-ir.net. Retrieved 2012-10-07.
  3. "ARIAD - News release". Phx.corporate-ir.net. 2011-03-17. Retrieved 2012-10-07.
  4. "UKMi New Drugs Online". Retrieved 2013-04-11.
  5. "ARIAD - News release". Phx.corporate-ir.net. 2011-06-06. Retrieved 2012-10-07.

External links

Template:Immunosuppressants